Who are Lysipressin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vasopressin intravenous infusion, desmopressin tablet, vasopressin - early initiation, desmopressin MELT formulation, Vasopressin, Arginine, DDAVP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lypressin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lysipressin — Competitive Intelligence Brief

Lysipressin (LYPRESSIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lypressin. Area: Metabolic.

marketed lypressin Vasopressin receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Lysipressin (LYPRESSIN) — Novartis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lysipressin TARGET	LYPRESSIN	Novartis	marketed	lypressin	Vasopressin receptor	1982-01-01
Vasopressin intravenous infusion	Vasopressin intravenous infusion	University of Sao Paulo	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptor V1a, V1b, and V2
desmopressin tablet	desmopressin tablet	University Hospital, Ghent	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor
vasopressin - early initiation	vasopressin - early initiation	The Cleveland Clinic	marketed	Vasopressor agent	Vasopressin receptor (V1 and V2)
desmopressin MELT formulation	desmopressin MELT formulation	University Hospital, Ghent	marketed	Vasopressin analog / Antidiuretic agent	V2 vasopressin receptor
Vasopressin, Arginine	Vasopressin, Arginine	Lars Wiuff Andersen	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptors (V1a, V1b, V2)
DDAVP	DDAVP	Chang, Steve S., M.D.	marketed	Vasopressin receptor agonist	V2 vasopressin receptor (AVPR2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (lypressin class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lysipressin — Competitive Intelligence Brief. https://druglandscape.com/ci/lypressin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab